NCT05162014View on ClinicalTrials.gov

To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin

CompletedOBSERVATIONAL
Enrollment

494,679

Participants

Timeline

Start Date

December 20, 2021

Primary Completion Date

September 12, 2022

Study Completion Date

September 12, 2022

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

empagliflozin

empagliflozin

DRUG

Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents

Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents

Trial Locations (1)

55216

Boehringer Ingelheim International GmbH, Ingelheim

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY